⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7445166 | 0.93 | — | — | |
| SCHEMBL32681267 | 0.84 | — | — | |
| SCHEMBL21798369 | 0.81 | — | — | |
| SCHEMBL18205525 | 0.77 | — | — | |
| SCHEMBL506367 | 0.75 | — | — | |
| SCHEMBL13840779 | 0.75 | — | — | |
| SCHEMBL2977576 | 0.75 | — | — | |
| SCHEMBL5131491 | 0.75 | ITGB3 (0.33) | — | |
| SCHEMBL27794282 | 0.73 | — | — | |
| Fluoride SCHEMBL3080411 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20240317706-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-117347520-A | Method for detecting content of residual monomer in polyethersulfone resin | 健帆生物科技集团股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023069720-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| EP-3849979-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | Novartis AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| CN-112996789-A | Antiviral pyridopyrazinedione compounds | 诺华股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020053654-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| US-20200079772-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-12 | — | — | US | disclosed |